OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	55
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	25
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	23
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	19
Learning pharmacometric covariate model structures with symbolic regression networks	17
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	17
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	13
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	13
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	12
Current practices for QSP model assessment: an IQ consortium survey	12
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	11
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	11
ADPO: automatic-differentiation-assisted parametric optimization	11
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	11
Imputation of missing clock times – application to procalcitonin concentration time course after birth	10
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	10
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	10
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	10
Informatics for toxicokinetics	9
Training the next generation of pharmacometric modelers: a multisector perspective	9
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	9
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	9
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	8
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	8
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	8
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	8
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
Thanks to our Reviewers of 2022!	7
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Scoping review of the role of pharmacometrics in model-informed drug development	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	6
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	6
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	5
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	5
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	5
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	5
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	5
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	5
Application of machine learning based methods in exposure–response analysis	5
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	5